FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
FDA General

Product Approval Summaries

FDA Review posts product approval summaries for the week ending 3/5/2022.

Biologics

Ocugen EUA Declined for Covid Vaccine

FDA declines to grant Ocugen an emergency use authorization for Covaxin for active immunization to prevent Covid-19 in individuals aged two to 18 year...

Federal Register

Patrick Bishop Debarred for 5 Years

Federal Register notice: FDA issues an order to debar Patrick Charles Bishop for a period of five years from importing or offering for import any drug...

Biologics

Sanofi Petitions FDA to Add Study Failure in Fluad Labeling

Sanofi petitions FDA to mandate a labeling change to Seqirus influenza vaccine products Fluad and Fluad Quadrivalent to reflect that a confirmatory st...

Human Drugs

CDER Updates Rare Disease Efforts

A CDER online post updates the Centers efforts to support rare disease drug development, particularly through data sharing initiatives that are import...

Human Drugs

GC Pharma Complete Response on Immune Globulin

FDA issues South Korea-based GC Pharma a complete response letter on its BLA for GC5107 (immune globulin intravenous (human), 10% Liquid) because the ...

Federal Register

Guide on Timely Product Recalls

Federal Register notice: FDA makes available a final guidance entitled Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C.

Federal Register

FDA Debars George Kuiper for 5 Years

Federal Register notice: FDA debars George Kuiper for a period of five years from importing or offering for import any drug into the U.S. due to felon...

Medical Devices

DexCom Breakthrough Status for Glucose Monitor

FDA grants DexCom a breakthrough device designation for its Dexcom real-time continuous glucose monitoring system for use in the hospital setting.

Human Drugs

Senators Ask CMS Not to Hurt Alzheimers Drug Access, Research

Sens. Collins and Capito ask the Centers for Medicare and Medicaid Services to ensure that its national coverage decision on Aduhelm does not restrict...